Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib plus enzalutamide in metastatic castration-resistant prostate cancer
NCT07287150Phase 2Recruiting
- Sponsor
- Roche
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of inavolisib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Roche. Started Mar 2026; status: recruiting.
02
Drugs
inavolisib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07287150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07287150.